108TiP CINDERELLA clinical trial: Using artificial intelligence-driven healthcare to enhance breast cancer locoregional treatment decisions

Le résumé fourni par la source

Breast cancer management often requires a delicate balance between effective treatments and preserving patient’s quality of life. Standardised methods to inform patients about different locoregional therapies and assess their aesthetic outcomes expectations are currently lacking. The CINDERELLA clinical trial addresses this gap by introducing an innovative artificial intelligence (AI)-driven tool designed for shared decision-making in breast cancer treatment. The study is expected to demonstrate the potential of AI in enhancing patient satisfaction and quality of life while maintaining high standards of care, leading us into the new era of breast cancer management, where technology and medical expertise converge to optimise aesthetic outcomes. This international randomised controlled trial uses the CINDERELLA APP. The APP showcases educational content and potential aesthetic outcomes of various locoregional treatments, aiding informed decision-making. The trial compares this AI-enhanced approach with standard informed consent processes. CANKADO is the core platform for physicians to manage patient APP content and gather data, ensuring privacy, data protection, and adherence to ethical AI principles. Eligibility criteria: non-metastaticbreast cancer patients eligible for either breast-conserving surgery or mastectomy with immediate reconstruction. Specific aims: the trial primarily aims to assess how well patients’ expectations align with actual aesthetic outcomes 12 months post-treatment. The correlation between AI tool predictions and patient self-evaluations, alongside examining health-related quality of life and resource utilisation are also being evaluated. Statistical methods: assessment of agreement levels between expectations and outcomes will utilise the Wilcoxon signed-rank test, with additional statistical tests and bootstrap techniques for inter-arm comparisons. Present accrual: recruitment began in August 2023, aiming to enrol at least 515 patients/arm across several countries. As of January 26, 2024, clinical study sites have successfully randomised 177 patients. NCT05196269. Champalimaud Research and Clinical Centre, Champalimaud Foundation (Lisbon, Portugal). European Union - HORIZON-HLTH-2021-DISEASE-04-04, Agreement No. 101057389.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.